Robert Greer, DO
Allergy & Immunology · Mobile, ALNPI 1912386194
Payments from drug & device makers
Across 576 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- CSL Behring$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$550
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,50596%
- Education$4204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,848 |
| GSK | 131 | $1,536 |
| CSL Behring | 63 | $1,313 |
| Sanofi | 61 | $1,256 |
| Regeneron Healthcare Solutions, Inc. | 62 | $1,117 |
| Genentech USA, Inc. | 31 | $550 |
| Novartis | 22 | $418 |
| Sanofi-aventis U.S. LLC | 4 | $332 |
| Optinose US, Inc. | 19 | $317 |
| Incyte Corporation | 15 | $301 |
| Biocryst US Sales Co., LLC | 11 | $233 |
| Pharming Healthcare, Inc. | 9 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $205 |
| Kaleo, Inc. | 13 | $197 |
| Amgen(2 entities) | 4 | $192 |
| Organon | 16 | $119 |
| Pfizer | 6 | $114 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| Lilly USA, LLC | 5 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $74 |
| Ionis Pharmaceuticals, Inc. | 3 | $55 |
| Cycle Pharmaceuticals Inc | 2 | $41 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Novo Nordisk | 2 | $33 |
| Grifols USA, LLC | 2 | $32 |
| Shire North American Group Inc | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,925 in reported general payments places this provider in the 65th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $70,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $42,849 |
| Spiriva RespimatTiotropium Bromide | 64 | $34,045 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $11,189 |
| Epinephrine | 59 | $10,746 |
| BreynaBudesonide/Formoterol Fumarate | 40 | $7,675 |
| Famotidine | 192 | $6,534 |
| Azelastine Hcl | 144 | $5,648 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $5,264 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,163 |
| DuleraMometasone/Formoterol | 13 | $4,520 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,380 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,153 |
| Fluticasone Propionate | 174 | $3,536 |
| Montelukast Sodium | 224 | $1,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,536 | $75,160107 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,848 | $54,03991 claims |
| Boehringer IngelheimSpiriva Respimat | $16 | $34,04564 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $10,74659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Mobile
- Lawrence SindelMobile$1.3M
- Michael GatesMobile$3K
- John AndersonHomewood$3.3M
- Joseph ForesterCullman$719K
- Njeri MainaBirmingham$241K
- Thomas AtkinsonBirmingham$155K
- William DavidsonDaphne$98K
- Michael PolcariBirmingham$86K
- Thomas ScottBessemer$65K
- Miranda CurtissBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.